Inflammatory bowel disease, alpha-synuclein aggregates and Parkinson’s disease: the InflamaSPark protocol

The hallmark of Parkinson’s disease (PD) is the accumulation of alpha-synuclein (AS) aggregates. Prior to the central nervous system involvement, PD establishes itself in the gut as a result of the complex interplay between microbiota, the host’s immune/neural systems and increased intestinal permeability. Inflammatory Bowel Disease (IBD) patients present a higher number of AS aggregates in the intestinal wall and an increased risk of developing PD. By studying AS aggregates in gut biopsy specimens of IBD patients and controls, this project aims to further clarify the pathophysiology of PD and to explore the potential of gut a biopsy for AS aggregates as a biomarker for prodromal PD.

Description

Communication abstract: Proceedings of the 5th International Congress of CiiEM - Reducing inequalities in Health and Society, held at Egas Moniz’ University Campus in Monte de Caparica, Almada, from June 16th to 18th, 2021.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords

inflammatory bowel disease Parkinson’s disease gut alpha-synuclein aggregates

URI

http://hdl.handle.net/10400.26/40113

Citation

Grunho M, Godinho C, Patita M, Mocanu I, Vieira AI, de Matos AA, Carregosa R, Marx F, Tomé M, Sousa-Catita D, Proença L, Outeiro T, Fonseca J. Inflammatory Bowel Disease, Alpha-Synuclein Aggregates and Parkinson’s Disease: The InflamaSPark Protocol. Medical Sciences Forum. 2021; 5(1):28. https://doi.org/10.3390/msf2021005028